Posted by Michael Wonder on 11 Apr 2022
Pfizer’s ALK targeted therapy Lorviqua passes reimbursement review
8 April 2022 - Pfizer’s Lorviqua (lorlatinib), a third generation anaplastic lymphoma kinase (ALK) targeted therapy, passed the review for health insurance coverage for the treatment of adult patients with ALK positive advanced non-small-cell lung cancer.
On Thursday, HIRA released the results of the drugs benefit appraisal committee’s meeting.
